Aurobindo

Net Sales are expected to increase by 5.1 percent Y-o-Y (up 3.2 percent Q-o-Q) to Rs 5,994.3 crore, according to ICICI Direct.

Teva settles patent dispute with Aurobindo Pharma

Aurobindo will have a licence to sell its Austedo generic product beginning April 2033

Aurobindo, Sun Pharma recall products in US market

The USFDA stated that Aurobindo Pharma USA Inc, a unit of Hyderabad-based drug major, is recalling 4,33,809 vials of Cyanocobalamin injection for being a "Subpotent Drug".

Aurobindo, Sun Pharma recall products in US market

As per the US health regulator, the New Jersey-based Sun Pharma Inc is recalling the affected lot due to "foreign matter identified as stainless steel microscopic wear particles mixed with punch lubricant oil and silicone particles from the dust cup".

Drug makers Glenmark, Aurobindo recall products in US

As per the latest enforcement report issued by the US Food and Drug Administration (USFDA), Glenmark's US-based unit is recalling various products in the US market.

Aurobindo Q1 PAT may dip 1.7% YoY to Rs 767.6 cr: ICICI Direct

Net Sales are expected to increase by 5.2 percent Y-o-Y (up 3.9 percent Q-o-Q) to Rs 6,233.7 crore, according to ICICI Direct.

Deregulation of vaccine rollout: What it means for pharma players

Dr Reddy’s, Gland Pharma, Strides, Cadila, Aurobindo are some of the names that merit a close watch as operating leverage plays out

Aurobindo Q4 PAT seen up 6% YoY to Rs. 901 cr: Sharekhan

Net Sales are expected to increase by 8.3 percent Y-o-Y (up 4.8 percent Q-o-Q) to Rs. 6,671.2 crore, according to Sharekhan.

Aurobindo Q2 PAT seen up 6% YoY to Rs. 675.1 cr: Emkay

Net Sales are expected to increase by 18.8 percent Y-o-Y (up 3.7 percent Q-o-Q) to Rs. 5,645.7 crore, according to Emkay.

Indian pharma majors deny allegations of price fixing in US

The companies have been accused of violating antitrust laws by fixing prices and allocating customers.

Aurobindo Q3 PAT seen up 11.5% YoY to Rs. 729 cr: Sharekhan

Net Sales are expected to increase by 12.7 percent Y-o-Y (up 2.9 percent Q-o-Q) to Rs. 4,888 crore, according to Sharekhan.

Aurobindo Q2 PAT may dip 23.1% YoY to Rs. 600 cr: Sharekhan

Net Sales are expected to increase by 6.3 percent Y-o-Y (up 10.9 percent Q-o-Q) to Rs. 4,714 crore, according to Sharekhan.

Aurobindo Q4 PAT seen up 25.3% YoY to Rs. 648.2 cr: Edelweiss

Net Sales are expected to increase by 19 percent Y-o-Y to Rs. 4,334.4 crore, according to Edelweiss.

Buy Aurobindo; target of Rs 825: Axis Direct

Axis Direct is bullish on Aurobindo has recommended buy rating on the stock with a target price of Rs 825 in its research report dated August 16, 2017.

Buy Aurobindo; target of Rs 740: HDFC Securities

HDFC Securities is bullish on Aurobindo has recommended buy rating on the stock with a target price of Rs 740 in its research report dated May 30, 2017.

Aurobindo Q4 PAT seen up 6.5% to Rs 616.2 cr: ICICI Securities

Net Sales are expected to increase by 4.6 percent Q-o-Q (up 9.1 percent Y-o-Y) to Rs 4087.6 crore, according to ICICI Securities. Aurobindo to report net profit at 616.2 crore up 6.5% quarter-on-quarter.

Sensex, Nifty under pressure amid volatility; GAIL, Aurobindo up

Benchmark indices and broader markets remained under pressure amid volatility in morning trade. GAIL and Aurobindo Pharma were the biggest gainers, up more than 2 percent.

Sensex, Nifty, Midcap sluggish; Brent crude, gold prices rise

Equity benchmarks as well as broader markets remained rangebound in noon trade with the Sensex hovering around 26500 level. Technology stocks continued to support the market whereas selling pressure was seen in banks, FMCG, select metals and pharma stocks.

Sensex continues to consolidate; Aurobindo, Hindalco slip 3%

The market continued to consolidate with the Nifty gyrating in a range of 8130-8150 in morning. ITC and ICICI Bank were the leading contributors while Infosys and HDFC continued to support the market.

Nifty breaks 8300, Sensex falls 100 pts; Tata Motors gains 2%

Lupin and Tata Motors were top gainers in early trade, up 2 percent each followed by Sun Pharma, BHEL, Hero MotoCorp and Aurobindo Pharma while Tata Steel, ITC, ONGC, Bharti Airtel, ICICI Bank, Idea Cellular and Bharti Infratel were losers.

Nifty ends at 7749, Sensex up 75 pts; Sun Pharma, TCS fall 2%

Jubilant Foodworks was the most active stock on exchanges after CSR report saying the bread available in India could be laced with toxic chemicals and may have toxic chemicals that can lead to thyroid disorders and cancer.

Nifty hovers around 7800, Sensex still in red; bank, IT drag

ICICI Bank, NTPC, Adani Ports, Bharti Airtel and Dr Reddy's Lab are the top losers, while Hindalco, Cipla, Reliance Industries, Lupin, Coal India and Aurobindo Pharma are top gainers.

Prefer Glenmark, Aurobindo, Cadila, Lupin: Emkay

Emkay Global Financial Services has come out with its report on Pharmaceuticals sector. The research firm has preferred Glenmark, Aurobindo, Cadila and Lupin from the space.

Nifty holds 6050; Aurobindo Pharma, Tata Motors most active

Aurobindo Pharma, Tata Motors, Cipla, Asian Paints, Aban Offshore, TCS, Bharti Airtel and HCL Technologies are most active shares on exchanges.

Aurobindo, Aban most active ahead of Q3 nos; Sensex weak

Aban Offshore and Aurobindo Pharma are among the most active shares on exchanges ahead of December quarter earnings today. Jet Airways topped the most active list after Etihad received aproval from CCI to buy 50.1 percent stake in Jet Privilege; the stock surged 10 percent.